Legend Biotech (LEGN) saw its stock price surge by 5.00% during intraday trading on Monday, as investors reacted positively to the company's announcement of an upcoming investor event. The biotechnology firm, known for its innovative cell therapies, is set to host a significant presentation during the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.
The investor event, scheduled for June 1, 2025, will feature Legend Biotech's top executives, including CEO Ying Huang, Ph.D., and CMO Mythili Koneru, M.D., Ph.D. They will be joined by expert clinicians to present the latest updates from the company's CARTITUDE development program. This program is crucial to Legend Biotech's pipeline, focusing on chimeric antigen receptor T-cell (CAR-T) therapies for multiple myeloma and other cancers.
The sharp increase in Legend Biotech's stock price reflects growing investor optimism about potential positive developments or data to be shared at the ASCO meeting. As one of the most prestigious oncology conferences globally, ASCO often serves as a platform for groundbreaking announcements in cancer research and treatment. The anticipation of favorable updates from the CARTITUDE program appears to be driving investor enthusiasm, contributing to the significant uptick in Legend Biotech's market value.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。